Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel

References

• Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 2006;16(Suppl 3): S156–62
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20:293–301
   PubMed Web of Science ®Google Scholar
• Chue P. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol 2006;20:38–56
   PubMedGoogle Scholar
• Tarricone I, Casoria M, Gozzi BF, et al. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. BMC Psychiatry 2006;6:11
   PubMedGoogle Scholar
• ADA. Consensus development conference on antipsychotic drugs and obesity and diabetes (American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity). Diabetes Care 2004;27:596–601
   PubMed Web of Science ®Google Scholar
• Technology Appraisal No. 43: Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence; June 2002
   Google Scholar
• Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251–67
   PubMed Web of Science ®Google Scholar
• Abilify Summary of Product Characteristics. London: Otsuka Pharmaceutical Europe Ltd; 2006
   Google Scholar
• Buckley PF. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs Today (Barc) 2003;39:145–51
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003;12: 655–62
   Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–71
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–90
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47–56
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325–37
   Google Scholar
• Marder SR, McQuade RD, Stock E. Aripiprazole in the treatment of schizophrenia: safety and tolerability in the short-term, placebo-controlled trials. Schizophr Res 2003;1916:1–14
   Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048–56
   PubMed Web of Science ®Google Scholar
• Centorrino F, Fogarty KV, Cimbolli P, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2005;11:241–7
   PubMedGoogle Scholar
• Millar H, Ganju P, Sullivan G. Long-term clinical effectiveness of aripiprazole versus other atypical antipsychotics: results from the Schizophrenia Trial of Aripiprazole (STAR). Oxford, UK: British Association for Psychopharmacology Summer Meeting; 2006
   Google Scholar
• Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312–20
   PubMed Web of Science ®Google Scholar
• Sullivan G, Ganju P, Millar H. Patient and caregiver preference for aripiprazole: results from the Schizophrenia Trial of Aripiprazole (STAR). Oxford, UK: British Association for Psychopharmacology Summer Meeting; 2006
   Google Scholar
• Gharabawi GM, Greenspan A, Rupnow MF, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry 2006;6:45
   PubMed Web of Science ®Google Scholar
• Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77–89
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115–21
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821–5
   Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr 2007;33:823–30
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:714–7
   Google Scholar
• Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004;65:1286–7
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005;15:249–58
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001;16:153–62
   Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51–7
   Google Scholar
• Hanssens L, L’Italien G, Marcus R, et al. Sexual dysfunction in a naturalistic, open-label study of aripiprazole and standard-of-care in community-treated patients with schizophrenia (the STAR trial). Toronto, Canada: American Psychiatric Association 159th annual meeting; 2006
   Google Scholar
• Mir A, Shivakumar K, McAllister V, et al. Change in sexual dysfunction on switching to aripiprazole. Schizophr Res 2006;81(Suppl):3–308
   Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391–9
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480–91
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005;26(Suppl 1):65–9
   PubMedGoogle Scholar
• Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251–8
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291–314
   PubMed Web of Science ®Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006;29:2329–30
   PubMed Web of Science ®Google Scholar
• Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology (Berl) 1989;97: 1–11
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005;65:1113–38
   Google Scholar
• Greden JF, Tandon R. Long-term treatment for lifetime disorders? Arch Gen Psychiatry 1995;52:197–200
   PubMed Web of Science ®Google Scholar
• Moncrieff J. Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses 2006;67:517–23
   PubMed Web of Science ®Google Scholar
• Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980;137:1395–8
   Google Scholar